Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,864,840
  • Shares Outstanding, K 1,246,266
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • EBIT $ 823 M
  • EBITDA $ 3,516 M
  • 60-Month Beta 0.17
  • Price/Sales 4.07
  • Price/Cash Flow 9.91
  • Price/Book 6.00

Options Overview Details

View History
  • Implied Volatility 24.56% ( +0.37%)
  • Historical Volatility 27.87%
  • IV Percentile 69%
  • IV Rank 46.32%
  • IV High 33.98% on 08/05/24
  • IV Low 16.44% on 12/05/23
  • Put/Call Vol Ratio 0.15
  • Today's Volume 5,093
  • Volume Avg (30-Day) 12,771
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 229,953
  • Open Int (30-Day) 247,570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.64
  • Number of Estimates 11
  • High Estimate 1.99
  • Low Estimate 1.13
  • Prior Year 1.72
  • Growth Rate Est. (year over year) -4.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.08 +4.77%
on 11/19/24
98.90 -8.81%
on 11/11/24
+2.03 (+2.30%)
since 10/22/24
3-Month
75.91 +18.81%
on 08/23/24
98.90 -8.81%
on 11/11/24
+14.29 (+18.83%)
since 08/22/24
52-Week
62.07 +45.30%
on 05/31/24
98.90 -8.81%
on 11/11/24
+14.49 (+19.14%)
since 11/22/23

Most Recent Stories

More News
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...

NVS : 104.28 (+0.41%)
GILD : 90.19 (+0.48%)
PFE : 25.65 (+2.07%)
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license application (sBLA) seeking approval of Dupixent for the treatment of chronic spontaneous...

GILD : 90.19 (+0.48%)
REGN : 738.00 (-0.87%)
PFE : 25.65 (+2.07%)
SNY : 48.28 (+0.63%)
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 117.76 (+0.43%)
BSX : 90.00 (-1.64%)
CRDL : 1.6200 (+2.53%)
GILD : 90.19 (+0.48%)
MDT : 86.21 (+1.73%)
Gilead Sciences (GILD) Stock Surges 4% on Positive Drug Trials and Promising Obesity and Weight Loss Treatments

Gilead Sciences (NASDAQ: GILD) witnessed a notable 4% surge in its stock price this morning, driven by a confluence of encouraging developments in drug trials, a positive industry outlook, and growing...

GILD : 90.19 (+0.48%)
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?

Bristol Myers Squibb Company BMY touched a 52-week high of $56.8 on Nov. 6.  The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months, regaining...

GILD : 90.19 (+0.48%)
PFE : 25.65 (+2.07%)
BMY : 58.87 (+1.10%)
Option Volatility And Earnings Report For November 11 - 15

This week, we have Home Depot, Alibaba, Disney, Shopify and Spotify all set to report among some other important names.

APP : 333.31 (+4.74%)
CVS : 58.01 (+1.59%)
TSLA : 352.56 (+3.80%)
SHOP : 106.96 (+0.45%)
GILD : 90.19 (+0.48%)
UPST : 74.06 (+3.68%)
MRNA : 41.11 (+7.48%)
PLTR : 64.35 (+4.87%)
DIS : 115.65 (+0.81%)
DKNG : 43.09 (-1.06%)
BABA : 83.13 (-2.86%)
SMCI : 33.15 (+11.62%)
3 Spectacular High-Yield Dividend Stocks to Buy in November

High yields aren't a warning indicator with these three stocks.

$SPX : 5,969.34 (+0.35%)
ABBV : 176.95 (+3.04%)
GILD : 90.19 (+0.48%)
PFE : 25.65 (+2.07%)
Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

XLV : 144.16 (+0.09%)
$SPX : 5,969.34 (+0.35%)
GILD : 90.19 (+0.48%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0025 (-16.67%)
TNXP : 0.1900 (-6.95%)
IBB : 137.96 (+1.37%)
JAGX : 1.0400 (+5.62%)
NVAX : 8.47 (+5.35%)
INO : 4.07 (+0.25%)
GILD : 90.19 (+0.48%)
MRNA : 41.11 (+7.48%)
VXRT : 0.6000 (+0.12%)
IBIO : 2.64 (+7.76%)
XBI : 96.24 (+2.06%)
PFE : 25.65 (+2.07%)
Gilead’s Stock Surge: What’s Fueling the Momentum?

Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.

GILD : 90.19 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 91.92
2nd Resistance Point 91.20
1st Resistance Point 90.70
Last Price 90.19
1st Support Level 89.48
2nd Support Level 88.76
3rd Support Level 88.26

See More

52-Week High 98.90
Last Price 90.19
Fibonacci 61.8% 84.83
Fibonacci 50% 80.49
Fibonacci 38.2% 76.14
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar